$EQ News

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease - Slideshow

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium Inc. (NASDAQ:EQ) Reports Narrower Q1 Loss But Slight EPS Miss as EQ504 Study Timeline Confirmed

Equillium Q1 EPS $(0.06) Misses $(0.05) Estimate

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

B. Riley Securities Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $6

Raymond James Initiates Coverage On Equillium with Strong Buy Rating, Announces Price Target of $6

Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists

Cantor Fitzgerald Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $10

Equillium Inc. (NASDAQ:EQ) Reports In-Line Q4 Earnings, Highlights Pipeline Progress and Runway into 2029

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium Q4 EPS $(0.04) Beats $(0.14) Estimate

Here’s What Roth Capital Thinks of Equillium (EQ) Stock

Equillium to Participate in the 38th Annual Roth Conference

Roth Capital Initiates Coverage On Equillium with Buy Rating, Announces Price Target of $12